The QualityStocks Daily Tuesday, December 13th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(OPGN) $0.2310 +84.80%

MarketClub Analysis(SMMT) $3.9100 +38.65%

Zacks(MRNA) $197.5400 +19.63%

The QualityStocks Daily Stock List

OpGen (OPGN)

StockMarketWatch, MarketClub Analysis, BUYINS.NET, QualityStocks, MarketBeat,, PennyStockScholar, InvestorPlace, OTCtipReporter, Penny Pick Finders, PennyStockProphet, Profitable Trader Authority, StockOodles, StreetInsider, TraderPower, Pennybuster, Trades Of The Day, StockOnion, Street Insider, Money Morning, The Street, TopPennyStockMovers, Investing Lab, INO Market Report and HotOTC reported earlier on OpGen (OPGN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OpGen Inc. (NASDAQ: OPGN) (FRA: 65O2) is a precision medicine firm that is focused on the development of molecular information services and products. The firm serves consumers in the United States as well as internationally.

OpGen Inc. is based in Gaithersburg, Maryland as was founded on January 22, 2001. The firm has a collaboration with the New York State Department of Health for developing a solution to detect, trace and manage antimicrobial-resistant infections in healthcare facilities.

OpGen Inc. uses molecular informatics and diagnostics to help fight infectious ailments. This is in addition to improving patient outcomes, helping clinicians with information on various life threatening diseases and reducing the spread of infections that are brought about by microorganisms which are multidrug-resistant.

OpGen Inc.’s product candidates include a vitro diagnostic test used to detect and identify different bacterial nucleic acids and genetic determinants of antimicrobial resistance in bacterial colonies separated from body sites or antimicrobial resistance in urine specimens dubbed the Acuitas AMR Gene Panel. Other products include PNA FISH and QuickFISH products. These diagnostic tests have been designed to detect infectious agents in positive blood cultures and have the tests have already been cleared by the FDA. Additionally, the firm provides Acuitas Lighthouse informatics systems, which merge hospital and patient information with clinical laboratory test results as well as offer insights and analytics that allow better management of multidrug resistant organisms in the patient care and hospital environment.

OpGen Inc. recently announced that it had received regulatory approval for its Curetis Unyvero System from the Chinese authorities. This move will allow the firm to market its product in China, which will help the firm grow as it extends its roots in the new market.

OpGen (OPGN), closed Tuesday's trading session at $0.231, up 84.8%, on 242,521,658 volume. The average volume for the last 3 months is 119.616M and the stock's 52-week low/high is $0.116/$1.33.

Maptelligent Inc. (MAPT)

We reported earlier on Maptelligent Inc. (MAPT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Maptelligent Inc. (OTC: MAPT) is focused on the provision of a cloud-based geographic platform which integrates data from alarms, cameras, sensors and accountability systems to develop actionable intelligence on an intuitive map display.

The firm has its headquarters in Henderson, Nevada and was incorporated in 1974, on August 7th. The firm serves consumers around the globe.

The company is party to a strategic partnership with NSION Technologies, which entails providing secure situational awareness using IoT sensors and real time video data streaming technology.

The enterprise’s platform also offers access information relevant to sites and structures that improve situational awareness and emergency response. It also offers a suite of applications and maps which afford consumers the ability to manage and maintain data in a mobile environment. For instance, building engineers can use the platform to manage maintenance schedules for elements like extinguishers, pull stations and alarm panels, which require regular attention, as well as public safety to develop incident preplans associated with building floor plans. In addition to this, the enterprise provides a cloud content management solution which manages and stores data associated with security solutions, professional services for safety assessments and system integration services. It serves various entities and organizations which are at risk from emergency incidents and threats like hospitals, schools universities, ports and shopping malls.

The company recently entered into a partnership with the Interactive Tactical Group, which will provide a range of services to the company’s clients as well as more accurate and reliable information in the indoor mapping capability space to consumers. This will be good for its investments as well as its growth.

Maptelligent Inc. (MAPT), closed Tuesday's trading session at $0.0009, up 80%, on 119,615,528 volume. The average volume for the last 3 months is 4.011M and the stock's 52-week low/high is $0.0004/$0.0108.

BeyondSpring Inc. (BYSI)

MarketBeat, MarketClub Analysis, QualityStocks, TraderPower, StockMarketWatch, InvestorPlace, Trading Concepts, TradersPro, StreetInsider, Schaeffer's and FreeRealTime reported earlier on BeyondSpring Inc. (BYSI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BeyondSpring Inc. (NASDAQ: BYSI) is a clinical stage biopharmaceutical firm that is engaged in developing and commercializing immune-oncology therapies.

The firm has its headquarters in New York and was incorporated in 2010 by Lin Qing Jia and Lan Huang. It is also known as Spring Pharmaceuticals. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm serves consumers around the globe.

The company is focused on improving outlooks and outcomes with its advanced immunotherapies. It is party to collaboration agreements with the University of Washington and the Fred Hutchinson Cancer Research Center.

The enterprise’s product portfolio comprises of a selective microtubule-binding immune-modulating agent dubbed Plinabulin, which has concluded phase 3 clinical trials evaluating its effectiveness in preventing chemotherapy-induced neutropenia. This immune-modulating agent is also undergoing phase 3 clinical trials testing its efficacy in treating later-stage non-small cell lung cancer. The enterprise is also developing Plinabulin in combination with different immune-oncology agents, including a CTLA-4 antibody dubbed ipilimumab, to help treat small cell lung cancer; and a PD-1 antibody dubbed nivolumab, to help treat non-small cell lung cancer. The formulation is also being developed in combination with radiation and PD-L1 or PD-1 antibodies to treat different types of cancer.

The firm is focused on getting approval for its plinabulin candidate in treating chemotherapy-induced neutropenia. The success of this formulation will improve clinical outcomes for patients with various indications while addressing their unmet medical needs, which will in turn boost investments into the firm.

BeyondSpring Inc. (BYSI), closed Tuesday's trading session at $1.03, up 35.9377%, on 4,029,731 volume. The average volume for the last 3 months is 3.433M and the stock's 52-week low/high is $0.542/$5.175.

Vincerx Pharma (VINC)

MarketBeat and QualityStocks reported earlier on Vincerx Pharma (VINC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vincerx Pharma Inc. (NASDAQ: VINC) is a clinical-stage biopharmaceutical firm that is focused on researching and developing therapies for the treatment of cancer.

The firm has its headquarters in Palo Alto, California and was incorporated in 2018, on December 19th by John C. Byrd, Soo In Hwang, Tom C. Thomas, Raquel E. Izumi and Ahmed M. Hamdy. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe, with a focus on the United States.

The company is focused on addressing the unmet medical needs for treating cancer. It uses its extensive oncology and development expertise to advance new therapies. The company’s pipeline is derived from a license agreement with Bayer.

The enterprise’s product pipeline comprises of a small molecule drug conjugate dubbed VIP236, for the treatment of solid tumors; an oral PTEFb/CDK9 inhibitor known as VIP217; and a cyclin-dependent kinase-9 inhibitor dubbed VIP152, for the treatment of patients with advanced cancer. VIP152 inhibits RNA polymerase II (RNAPII) phosphorylation, which helps prevent transcription elongation and blocks the expression of genes which promote cancer. It also develops VIP924 and VIP943 for the treatment of hematologic malignancies.

The firm recently released preliminary clinical data for its VIP152 candidate and is currently focused on aligning its clinical trial design with the Project Optimus Initiative by the FDA. The success and approval of this formulation will not only benefit patients with different types of cancer but also bring in more investors into the firm.

Vincerx Pharma (VINC), closed Tuesday's trading session at $1.08, up 58.8235%, on 4,700,710 volume. The average volume for the last 3 months is 10,906 and the stock's 52-week low/high is $0.6311/$10.70.

Duos Technologies (DUOT)

Wall Street Resources, QualityStocks, MarketBeat, SmallCapVoice and InvestorPlace reported earlier on Duos Technologies (DUOT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Duos Technologies Group Inc. (NASDAQ: DUOT) is a company focused on designing, developing, deploying and operating intelligent technology solutions.

The firm has its headquarters in Jacksonville, Florida and was incorporated in 1994, on May 31st. It operates as part of the software-application industry, under the technology sector. The firm serves consumers in North America, with a focus on those in the United States.

The technology platforms used in the company’s solutions include an integrated platform dubbed Truevie360, which develops and deploys AI algorithms, including machine learning, object detection, computer vision and deep neural network-based processing for real-time applications; and an enterprise information management system known as Centraco.

The enterprise’s proprietary applications include the Railcar Inspection Portal, which has been designed for the automated inspection of transit and freight trains while in motion; Thermal Undercarriage Examiner; Enterprise Command and Control Suite for information consolidation, connectivity, and communications; Vehicle Undercarriage Examiner to inspect the undercarriage of rail-cars; and a proprietary intelligent system known as the Automated Logistics Information Systems, which automates security gate operations. It also offers maintenance and technical support services; IT asset management services for data center operators; software licensing with optional hardware sales; consulting and auditing; and training services.

The firm’s latest financial results show significant increases in its revenues, with its CEO noting that they remained committed to making additional investments and expanding the range of services they provided. This will bring in additional revenues into the firm while also opening up the firm to new growth opportunities.

Duos Technologies (DUOT), closed Tuesday's trading session at $2.09, off by 3.8638%, on 11,008 volume. The average volume for the last 3 months is 1.299M and the stock's 52-week low/high is $2.01/$6.50.

Golden Sun Education Group (GSUN)

We reported earlier on Golden Sun Education Group (GSUN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Golden Sun Education Group Ltd (NASDAQ: GSUN) is a holding firm that is principally engaged in the provision of educational services.

The firm has its headquarters in Shanghai, China and was incorporated in 1997. It operates as part of the education and training services industry, under the consumer defensive sector. The firm serves consumers in the People’s Republic of China.

The company mainly operates through the Primary and Secondary Schools Services; Tutorial; and Other Services segments. It has more than two decades of experience in offering educational services that focus on the development of each of its student’s potential and strengths, and the promotion of lifelong skills and interests in learning. The company primarily offers its services through operating subsidiaries.

The enterprise mainly provides professional financial education and training services. Its professional financial education services cover a range of categories including finance, tax and accounting, among others, in forms of online and in-person classes. This helps enterprises to improve the quality of financial operation and enables students to pass their professional certification examinations. It also provides middle and elementary schooling services; non-English foreign languages tutorial services; and logistics and consulting services. The logistics and consulting business primarily provides catering services to affiliated schools.

The firm, which recently announced its latest financial results, remains focused on expanding its business and market share, growing its business and achieving long-term development goals. This will improve brand awareness, expand its customer base and help create significant value for its shareholders.

Golden Sun Education Group (GSUN), closed Tuesday's trading session at $1.3, off by 14.4737%, on 1,307,822 volume. The average volume for the last 3 months is 26,718 and the stock's 52-week low/high is $1.13/$95.00.

Lisata Therapeutics (LSTA)

We reported earlier on Lisata Therapeutics (LSTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lisata Therapeutics Inc. (NASDAQ: LSTA) (LON: OHS8) (FRA: 8NE) is a clinical-stage biopharmaceutical firm that is focused on the development and commercialization of cellular therapies that help promote the regeneration of damaged tissues and disease reversal.

The firm has its headquarters in Basking Ridge, New Jersey and was incorporated in 1980. Prior to its name change on September 15th 2022 as a result of a merger with Cend Therapeutics, the firm was known as Caladrius Biosciences Inc. Before it changed its name in June 2015 to Caladrius Biosciences Inc., it was known as NeoStem Inc. The firm operates as part of the biotechnology industry, under the healthcare sector. It serves consumers around the globe.

The enterprise develops innovative treatments based on clear differentiation and rigorous data applied in areas of high unmet medical need. Its investigational product candidate, LSTA1, has been designed to modify the tumor microenvironment to allow anti-cancer drugs to penetrate solid tumors more effectively. Its other product candidates include a CD34+ SAKIGAKE and ATMP designation recipient dubbed HONEDRA, which has been designed to treat critical limb ischemia; and a CD34+ cell therapy known as CLBS201, which is indicated for the treatment of pre-dialysis patients suffering from kidney disease. The enterprise also develops XOWNA, which is currently in phase 2b trials evaluating its efficacy in treating coronary microvascular dysfunction.

The company, which recently announced its latest financial results, remains focused on advancing its pipeline of candidates that target oncology and ischemic disease indications. The success and approval of these candidates will increase investments into the company while also benefiting patients with various indications.

Lisata Therapeutics (LSTA), closed Tuesday's trading session at $2.866, off by 4.7841%, on 26,723 volume. The average volume for the last 3 months is 42,552 and the stock's 52-week low/high is $2.8611/$17.10.

Dolphin Entertainment (DLPN)

MarketClub Analysis, TradersPro, MarketBeat, InvestorPlace, StockMarketWatch, StreetInsider, QualityStocks, The Street, Broad Street, Trading Concepts and BUYINS.NET reported earlier on Dolphin Entertainment (DLPN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dolphin Entertainment Inc. (NASDAQ: DLPN) is an independent entertainment marketing and premium content development firm.

The firm has its headquarters in Coral Gables, Florida and was incorporated in 1995, on March 7th. Prior to its name change in July 2017, the firm was known as Dolphin Digital Media Inc. It operates as part of the advertising agencies industry, under the communication services sector. The firm serves consumers in the United States.

The enterprise operates through the Entertainment Publicity and Marketing (EPM); and Content production (CPD) segments. The Entertainment Publicity and Marketing segment provides entertainment content marketing, public relations, strategic communications, creative branding, social media and digital marketing, entertainment marketing and talent publicity services. This is in addition to producing promotional video content. This segment comprises of The Door, 42West, Shore Fire Media and Viewpoint. On the other hand, the Content Production segment is involved in the production and distribution of digital content and feature films. It also provides strategic marketing and publicity services to corporations and individuals in the entertainment, music and hospitality industries; and public relations counsel, media strategy and marketing direction for video game publishers, as well as eSports leagues and other entities in the gaming industry. This segment comprises of Dolphin Films and Dolphin Entertainment.

The company has acquired Socialyte and Lytehouse, both of which are influencer marketing agencies. This move will not only help create value for its shareholders and increase its market share of the industry but also open the company up to new growth and investment opportunities.

Dolphin Entertainment (DLPN), closed Tuesday's trading session at $2.27, off by 3.4043%, on 42,552 volume. The average volume for the last 3 months is 35,964 and the stock's 52-week low/high is $2.25/$9.68.

Innovative Eyewear (LUCY)

ShamrockCap and Penny Stock reported earlier on Innovative Eyewear (LUCY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Innovative Eyewear Inc. (NASDAQ: LUCY) is a company focused on the development and sale of smart eyeglasses and sunglasses.

The firm has its headquarters in Miami, Florida and was incorporated in 2017 by David Eric Cohen, Konrad Dabrowski and Harrison Gross. It operates as part of the medical instruments and appliances industry, under the healthcare segment. The firm serves consumers across the globe.

The company is focused on a single ambitious objective; to evolve what the world thinks a pair of glasses can be. It is party to a partnership with Lucyd and operates as a subsidiary of Lucyd Limited.

The enterprise's flagship product is Lucyd Lyte glasses, which allow the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free, using Bluetooth. It also offers standard frames and titanium frames for non-prescription, polarized sunglass and blue light blocking glasses. This is in addition to providing a social media application dubbed Vyrb, which enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. The enterprise provides its products through e-commerce primarily via its website and Amazon; as well as through a network of independent eyewear stores.

The firm recently licensed Nautica, a global lifestyle brand, for smart eyewear. This move will not only help the firm to occupy a larger share of the market and better meet consumer needs but also extend the firm’s global reach, which will positively influence revenues and investments into the firm.

Innovative Eyewear (LUCY), closed Tuesday's trading session at $0.96, off by 4.62%, on 35,964 volume. The average volume for the last 3 months is 395,882 and the stock's 52-week low/high is $0.861/$7.00.

Alliance Resource Partners L.P. (ARLP)

The Online Investor, Zacks, TradersPro, QualityStocks, The Street, MarketBeat, InvestorPlace,, MarketClub Analysis, TopStockAnalysts, Dividend Opportunities, The Wealth Report, TheStockAdvisor, The Motley Fool, Money Morning, StreetAuthority Daily, Market Intelligence Center Alert, BUYINS.NET, Investing Daily, Daily Wealth, Daily Trade Alert, Rick Saddler, TraderPower, SmarTrend Newsletters, The Growth Stock Wire, Wealth Insider Alert, TheOptionSpecialist, TheStockAdvisors, Trading Concepts, Daily Markets, Trades Of The Day, Eagle Financial Publications, Early Bird, FNNO Newsletters, Greenbackers, Insider Wealth Alert,, Investor Update, Short Term Wealth, Top Pros' Top Picks, Leeb's Market Forecast, TheTradingReport, TheStreet Offers, Money and Markets, StreetInsider and Investment U reported earlier on Alliance Resource Partners L.P. (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, the International Energy Agency stated that the capacity to produce renewable energy globally would increase by more than 70% in the next five years. The agency believes that this will mainly be driven by energy security concerns as more countries turn to the use of renewable sources of energy such as wind and solar in an effort to decrease their reliance on fossil fuels.

According to the agency’s forecast, renewable energy will overtake coal to become the biggest source of electricity globally by 2025. The International Energy Agency expects that during this period, capacity will reach 5640 GW, which represents an increase of 2400 GW. This increase is significantly higher than the growth the agency predicted a year ago, as higher prices of electricity and fuel make renewables even more attractive to consumers as well as investors.

Faith Birol, the agency’s executive director, stated that while the use of renewable energy was increasing, the current worldwide energy crisis had pushed the sector into even faster growth.

This comes after Russia’s invasion of Ukraine affected the energy supply chain and forced countries in Europe that relied primarily on gas from Russia, such as Germany, to look for alternatives as quickly as possible. Birol added that the global energy crisis would be a turning point toward the use of cleaner energy.

Other countries, such as India, China and the United States, are also adopting market reforms and policies to introduce renewables at a faster pace than previously planned. The International Energy Agency also predicted that China could, in the next five years, make up about one-half of new renewable power capacity additions globally.

On a global scale, the agency stated that the increase in the use of these cleaner energies would also make it easier to meet the 1.5o C global warming target to limit climate change. The target was adopted during COP 21 and set under the 2015 Paris Agreement, which entered into force in 2016.

The report also visualized a scenario where the increasing use of renewable energies would exceed the forecast by 25%, which would make it even easier for the global target to be reached. It theorized that developed nations could help make this possible by using more renewables in transport and heating, and streamlining processes to grant permits.

Developing nations could also address weak grid infrastructures and policy uncertainties while also introducing affordable financing to ease the adoption of renewable energies. In the meantime, fossil fuel producers such as Alliance Resource Partners L.P. (NASDAQ: ARLP) will continue to enjoy a stable market for coal and other fuels.

Alliance Resource Partners L.P. (ARLP), closed Tuesday's trading session at $21.52, up 0.32634%, on 396,021 volume. The average volume for the last 3 months is 782,227 and the stock's 52-week low/high is $10.00/$27.63.

BIT Mining Limited (BTCM)

QualityStocks, MarketClub Analysis, Schaeffer's and StocksEarning reported earlier on BIT Mining Limited (BTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BIT Mining (NYSE: BTCM), a leading technology-driven cryptocurrency mining company, has announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its Class A ordinary shares (the “ADS Ratio”), par value US$0.00005 per share. The change is from the current ADS Ratio of one (1) ADS to ten (10) Class A ordinary shares, to a new ADS Ratio of one (1) ADS to one hundred (100) Class A ordinary shares (the “ADS Ratio Change”). BIT Mining anticipates that the ADS Ratio Change will be effective on or about Dec. 23, 2022. For holders, the ADS Ratio Change will have the same effect as a one-for-ten reverse share split. BIT Mining’s ADSs will continue to be traded on the New York Stock Exchange under the BTCM ticker symbol.

To view the full press release, visit

About BIT Mining Limited

BIT Mining is a leading technology-driven cryptocurrency mining company with a long-term strategy to create value across the cryptocurrency industry. Its business covers cryptocurrency mining, mining pool, data center operation and miner manufacturing. The company owns the world’s top blockchain browser and the comprehensive mining pool business operated under, providing multicurrency mining services, including BTC, ETH and LTC. The company also owns a 7-nanometer cryptocurrency mining machine manufacturer, Bee Computing, enabling the company’s self-efficiency through vertical integration with its supply chain.

BIT Mining Limited (BTCM), closed Tuesday's trading session at $0.2148, off by 7.8112%, on 795,909 volume. The average volume for the last 3 months is 490,957 and the stock's 52-week low/high is $0.1888/$7.19.

Keros (KROS)

StreetInsider, Trades Of The Day, MarketBeat and FreeRealTime reported earlier on Keros (KROS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Keros (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders, announced that it presented clinical and preclinical data at the 64th American Society of Hematology (“ASH”) Annual Meeting and Exposition. The event was held in person and virtually from Dec. 10 -13, 2022. “We are pleased to present clinical and preclinical data from our lead hematological programs at ASH this year. In our ongoing phase 2 clinical trial in MDS, we observed a sustained response with longer-term treatment with KER-050 across all transfusion burdens. Data from our ongoing phase 2 trial in MF support the potential for KER-050 to treat multiple cytopenias as either a monotherapy or in combination with ruxolitinib,” said Jasbir S. Seehra, Ph.D., president and CEO of Keros. “In addition, clinical data from one IRIDA patient in our phase 2 clinical trial of KER-047 was suggestive of iron redistribution consistent with KER-047’s mechanism of action.”

To view the full press release, visit

About Keros Therapeutics Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Keros is a leader in understanding the role of the TGF-β family of proteins, which are master regulators of RBC and platelet production as well as of the growth, repair and maintenance of a number of tissues, including blood vessels and heart tissue. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with MF. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Keros’ third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders associated with cardiac hypertrophy.

Keros (KROS), closed Tuesday's trading session at $51.77, up 9.4041%, on 493,575 volume. The average volume for the last 3 months is 243.911M and the stock's 52-week low/high is $24.38/$68.29.

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announcedRandy Marion Automotive (“RMA”) as the first dealer group partnerfor MULN’s commercial EV lineup, which is set to launch in the 2023. The commercial EV line includes Class 1-3 cargo van andcab chassis offerings and Bollinger Motors Class 4-6 chassisproducts. “We are impressed with Mullen Automotive’s EV lineup,their speed to market and, most notably, their focus on anunderserved commercial market for EV vehicles,” said Randy Marion,CEO and founder of RMA. “This is especially obvious when youconsider what has taken place in the Class 1 light cargo vancategory. OEMs have all exited from the commercial Class 1 vansegment, leaving the door wide open for Mullen’s EV lineup.” Toview the full press release, visit


A report authored by Fitch Solutions suggests that electric vehicle makers from China have set their eyes on theEuropean mass market and could make significant inroads next year,followed by an even bigger onslaught in the years to come. Thereport says that the Chinese automakers are likely to find a hardertime breaking into the premium EV market, but that goal isn’t analtogether impossible one once the vehicle makers establishthemselves in the mass market segment of the industry. This isbecause premium market buyers who are used to cruising around inAudis, BMWs, Porsche or Mercedes Benz are unlikely to easily taketo brands such as BYD, Xpeng or NIO. The report indicates that atthe moment, Chinese-made EVs have a 5% share of the market inEurope. This could bump up to 15% by 2025. The major brands inEurope lean more toward the upper-tier EVs due to the stringentemissions controls in their jurisdictions and the fact that thepremium segment offers better profit margins than the mid-marketelectric vehicles. This bias is exactly what the Chinesemanufacturers are looking to exploit, Fitch Solutions says. Anotherpossible hurdle is likely to be a political one. The Chinese don’thave a good reputation for observing human rights, and the newsabout demonstrations against harsh lockdown measures isn’t doingtheir PR any good. How they navigate these hurdles could make orbreak their entry into Europe, giving automakers such as Mullen Automotive Inc. (NASDAQ: MULN) more space to gain a foothold and establish themselves in thatmarket.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $0.2139, up 10.829%, on 247,654,196 volume. The average volume for the last 3 months is 31,690 and the stock's 52-week low/high is $0.18/$6.45.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SideChannel is a company making cybersecurity accessible andsimple, especially for small and mid-sized businesses (“SMBs”)

The company provides cybersecurity services in the form of virtualCISOs (“vCISOs”), engineering services that enable the vCISOs toprovide operational day-to-day security and privacy to clients, andproprietary security software called Enclave

SideChannel’s differentiator from its competition is its team ofexperts, and recently the company hired IT and cybersecurityveteran Sean Higgins as Principal Consultant

In this role, Sean will help client companies’ CISOs and seniormanagement evaluate and have greater levels of confidence in theirsecurity programs

SideChannel (OTCQB: SDCH), a company focused on making cybersecurity more accessible andsimple, especially for small and mid-sized businesses (“SMBs”),recently expanded its team with the hiring of Sean Higgins asPrincipal Consultant (


SideChannel Inc. (OTCQB: SDCH) CEO Brian Haugli was a guest on “Mornings with Maria,” a FoxBusiness program that features industry titans and economic expertsdiscussing the major news and themes driving the business day andthe market moves. Haugli discussed rising concerns that TikTok, anapplication owned by China-based DanceByte, presents a nationalsecurity issue. Those concerns have been fueled by GOP leaderscalling for the application to be banned and the FBI issuing astatement about the possibility that the Chinese government coulduse the app to control data collection on millions of users,control the recommendation algorithm or control software onmillions of devices. “[TikTok] is an application that runs on yourphone, widely popular, but this application has access to things onyour phone that you might hold dear,” said SideChannel CEO BrianHaugli during the interview. “Your contacts, your locations, yourbuying intent, your shopping history, your browser history— everything that you probably want to keep private. Thatapplication has access to your phone in a way that could give themaccess to all of that information. Why it would be considered anational security threat, in my opinion, is that you’re now able tobuild a profile on every individual who is using that application.You’re able to take that information in aggregate, and in the handsof a foreign national, a foreign party, what could be done, right?. . . We have the opportunity to put pressure on Google and Appleto remove this application from the store. We have the opportunityto build better regulations within the United States and canactually set up infrastructure that could block access to this dataor this data leaving our environment. It’s not something that theU.S. has set up today, and it’s something that I think we very muchneed.” A provider of cybersecurity services and technology foremerging and middle-market companies, SideChannel also announcedthat it is partnering with InvestorBrandNetwork (“IBN”) for itscorporate communications. IBN is a multifaceted financial news andpublishing company for private and public entities. The agreementcalls for IBN to leverage its investor-based distribution networkof more than 5,000 syndication outlets along with multiplenewsletters, social media channels, wire services and blogs togenerate greater awareness for SideChannel. To view the fullinterview, visit To view the full press release, visit

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.


Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.


Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Tuesday's trading session at $0.12, up 9.0909%, on 31,690 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.45/$.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Hillcrest Energy Technologies recently unveiled a commercialprototype of its 800-volt, 250-kilowatt Zero Voltage Switching(“ZVS”) traction inverter

The production of a commercial prototype comes only months afterthe company had published white papers, extolling the potential oftheir revolutionary technology

The inverter will be developed and integrated alongside Hillcrest’spartners, Hercules Electric Mobility as well as a separate Tier 1automotive supplier

The company envisions its inverter technology being deployed withbatteries, electric motors, generators, fuel cells and any otherpower source requiring power conversion

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF), a clean technology company focused on developing transformativepower conversion technologies, has recently announced thecompletion of its 800-volt, 250-kilowatt Zero Voltage Switching(“ZVS”) traction inverter commercial prototype. Whilst initiallydirected towards the electric vehicle industry, Hillcrests ZVSinverter technology can eventually be applied with batteries,electric motors, generators, fuel cells or virtually any otherpower source where power conversion is needed.

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Tuesday's trading session at $0.0803, up 2.033%, on 7,490 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.072/$0.1724.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

  • 66% of US consumers (80% of consumers aged 18-34) are willingto pay more for products made with sustainability in mind
  • The luxury home décor market is expected to reach $207 billionby 2027, growing from $118 billion in 2020 at a CAGR of 5.14%
  • Coyuchi guarantees the highest environmental and ethicalstandards through its certifications – The Global OrganicTextile Standard (“GOTS”), Fair Trade Certified, and MADESAFE(R)
  • Coyuchi is built upon four foundational pillars – protectingthe environment, innovating circular design, livingsustainably, and enriching the community – with over 1400 SKUsmade from 100% organic cotton
  • The company is currently accepting investment throughRegulation A+ offerings

Coyuchi is setting the gold standard in sustainable luxury home goods,offering sustainably produced luxury organic bedding, sheets,towels, apparel, and other home goods for the environmentallyconscious home. For 30 years, Coyuchi has explored organic farmingand sustainable textiles, and guarantees the highest environmentaland ethical standards through its acquisition of certifications,including The Global Organic Textile Standard (“GOTS”), Fair TradeCertified, and MADE SAFE(R). Backed by a seasoned leadership team,a robust e-commerce shopping experience, and a healthy customerbase driving the fast-growing organic luxury market, Coyuchi ispositioned to propel its new growth phase as the world awakens tosustainability at scale.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values ( With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through, creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News


REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

Earlier this year, the General Assembly of Virginia established a task force to study the increase in unregulated delta-8 THC products in the state; theassembly has recommended tougher rules for businesses that sellthese products.Delta-8 THC is a psychoactive substance found in marijuana. Similar to delta-9THC, which is found abundantly in marijuana, the compound producesa high when consumed, either through smoking or consuming anedible. The state of Virginia legalized the recreational use of cannabis for individuals aged 21 and above in July 2021. Under the enactedlaw, individuals can legally possess up to an ounce of cannabis.These tighter regulations targeting products that were previouslyunregulated is likely to give the clients of companies such as REZYFi Inc. a more level playing field where all players abide by the samerules.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.


REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.

Recent News


Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience is a global innovator in drug delivery platformswhose patented DehydraTECH(TM) technology has demonstrated theability to improve the bioavailability and increase the speed ofonset of many drugs

In calendar 2022, the company achieved a number of milestones invarious areas, including research programs, receipt of patents, andlicensing agreements

Lexaria started and completed its fourth and most comprehensivehypertension study yet, investigating the capabilities ofDehydraTECH-CBD, with the study showing that its formulationresulted in a sustained reduction in blood pressure over the studyperiod (five weeks)

The company has also started investigating DehydraTECH-CBD as apotential therapeutic for the treatment of dementia and diabetesand is planning to begin another study on DehydraTECH-nicotinepouch performance

Over the course of the year, Lexaria was granted four new patents,and entered into separate licensing agreements with four newpartners

In his concluding remarks in this year’s letter to shareholderspublished January, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka underlined that “Management of [the company] feelswe are on track, on schedule, and on budget to deliver what we hopeand expect will be great results in 2022” ( Since then, the company has achieved crucial milestones that canwell be described as “great results,” and rightly so. Thesemilestones are centered around Lexaria’s patented DehydraTECH(TM)drug delivery technology.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $2.96, even for the day, on 6,958 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$5.28.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

The NanoAbs may provide improve upon existing treatments such asPaxlovid, which has several contraindications

The company’s pipeline of alpaca-derived NanoAb therapies aims toaddress diseases with large underserved medical needs, includingCOVID-19, asthma, psoriasis, and more

The global COVID-19 therapy market was valued at $16.8 billion in2021 and is expected to grow at a CAGR of 20%, resulting in a valueof $35.42 billion by 2025

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing andcommercializing innovative immunotherapeutic products primarily forthe treatment of infectious and autoimmune diseases, was featuredin the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution viawidespread syndication channels. BiondVax’s CEO Amir Reichmanjoined the latest episode to introduce the company and discuss its recent developmentefforts focused on innovative nanosized antibody (“NanoAb”)therapies addressing diseases underserved by current treatments andwith large and growing markets. “[While attempting to develop theuniversal influenza vaccine], BiondVax built a state-of-the-artfacility in Jerusalem. It’s a manufacturing facility that includesalmost all of the steps of biological production… What we didn’thave at the time that I joined was the IP… We ended up contractingwith the Max Planck Institute for Multidisciplinary Sciences andthe University Medical Center Göttingen,” Reichman said during theinterview with IBN’s Stuart Smith. “With these two institutes, weentered three contracts. One is an exclusive license fordevelopment and commercialization of a self-inhaled COVID-19therapeutic. The second was an accompanying research collaborationagreement… The third contract was a five-year strategic researchcollaboration contract with these two institutes for the discoveryand development of nanobodies for the treatment of additionaldiseases such as psoriasis, psoriatic arthritis, asthma and maculardegeneration.” To view the full press release, visit


An analysis conducted on a 2021 poll has released resultsindicating that most patients suffering from plaque psoriasis have reported symptoms in intertriginous areas, which sometimesprevents them from seeking medical guidance. The researchers lookedinto the sexual, psychosocial and mental impact of such symptoms onthe affected patients and found that roughly two-thirds of patients would like to have therapy options to treat psoriasis in theseareas. A team of U.S. researchers, led by Teri Greiling, conductedthe analysis of the Harris Poll’s findings and presented theirresults at this year’s Society of Dermatology Physician Assistantsannual meeting. Greiling is the associate program director ofresearch and dermatology at the School of Medicine in Oregon Health & Science University.Companies such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are focused on finding better treatments for ailments such aspsoriasis so that patients will no longer have to be embarrassedeach time a flare up occurs and a doctor has to examine them oradminister medicine in intertriginous parts of the body.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Tuesday's trading session at $10.31, off by 4.093%, on 9,436 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $5.335/$34.90.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development andmanufacturing of rare cannabinoids and cannabinoid analogs,announced that Jonathan Tegge, a member of Brio Financial Group,will shoulder the role of interim CFO effective Dec. 12, 2022. Theannouncement accompanied the news that InMed has signed a servicecontract with Brio Financial Group to provide senior financialleadership and bookkeeping services. A financial and managementconsulting group based in New Jersey, Brio outsources financialmanagement and financial reporting support to small- andmiddle-market entities. Currently, the Brio team providesconsulting services to some 50 private and publicly tradedcompanies. InMed also stated that its auditor, KPMG LLP; InMed’saudit committee of the company’s board of directors approved MarcumLLP as the new company auditor. “We are delighted to engage Marcumas the company’s new auditors,” said InMed Pharmaceuticals CEO EricA. Adams in the press release. “We believe that Marcum's breadth ofexpertise and its focus on mid-sized companies, includingcross-border operations, makes Marcum well suited to support ourefforts to deliver the high level of financial transparency andreporting to which our shareholders are accustomed.”

To view the full press release, visit

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Tuesday's trading session at $1.94, off by 0.512821%, on 77,260 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.87/$38.50.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots, today announced the largest single contract in the company’s history alongside twonew contracts from cities in New York and Georgia. Under thecontracts, Knightscope will deploy 12 K5 Autonomous Security Robots(“ASRs”), 2 K1 Blue Light Towers and 2 K1 Call Boxes.

The announcement reads, “A key decision-making factor for thelarger client was the K5’s unmatched capabilities that are not partof the current security program. The company will be deploying ASRsas part of an overall ‘layered’ approach to give them unprecedentedeye-level views and coverage. The ASRs will deter crime, criminaltrespassing and loitering while providing their employees withgreater personal safety.”

“Knightscope continues to deliver on its promise to rapidly growthe company and help make the United States of America the safestcountry in the world,” said William Santana Li, chairman and CEO atKnightscope. “Today’s announcement further supports my recent public address where we project tripling our annualized revenue over the nexttwelve months.”

To view the full press release, visit

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Tuesday's trading session at $1.655, off by 3.2164%, on 1,380,151 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.65/$27.50.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Secretary Xavier Becerra of the U.S. Department of Health and Human Services recentlyrevealed during an event on overdose prevention that the agency wasfocused on completing a review on federal marijuana scheduling, aswas recently directed by President Joseph Biden. President Biden ordered that a schedulingreview be carried out by the department following his issuance ofmarijuana pardons, which saw thousands of individuals convicted of simple marijuana possession under federal law being released. The health secretary has thusfar raised the issue with the head of the FDA, Dr. Robert M. Califf. The departmenthead added that the FDA was committed to supporting evidence-basedpolicies for cannabis, noting that the science-focused approachalso applied to policy decisions on other drugs. The entirecannabis industry, including entities such as Flora Growth Corp. (NASDAQ: FLGC), will be following the scheduling review process closely since thepolicy recommendations made could have far-reaching implicationsfor the future of the industry.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Tuesday's trading session at $0.29, off by 2.6846%, on 1,311,541 volume. The average volume for the last 3 months is 1.29M and the stock's 52-week low/high is $0.2745/$2.38.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies, Inc. (Nasdaq: FRGT), (“Fr8Tech”), atechnology company based on its custom-developed Fr8App platformwhich is powered by AI and machine learning that offers a real-timeportal for B2B cross-border shipping and domestic shipping withinthe United States-Mexico-Canada (NAFTA) region, discloses itsintegration with FourKites®, a leading supply chain visibilityplatform in the U.S.

With this integration, Fr8App's platform can send automaticlocations to the FourKites®'s New Unified Customer Interface sothat enterprise companies using the new FourKites®'s product areable to receive real time locations from drivers using Fr8App.

“A leader in track and trace in the U.S., FourKites® is used bymany enterprise companies and some of our current customers. Withthis integration we empower our Fr8Radar product, making the trackand trace monitoring process more efficient for our customerscurrently using FourKites®'s monitoring system,” said JavierSelgas, CEO of Fr8Tech. “By integrating with Fr8App, FourKites® hasvalidated our services and increased our access to new, largecustomers. We believe this alliance will be a long-term revenuedriver and we look forward to reporting on our progress.”

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Tuesday's trading session at $0.2617, off by 4.3494%, on 674,040 volume. The average volume for the last 3 months is 668,326 and the stock's 52-week low/high is $0.1799/$8.734.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

MDMA is a stimulant drug that causes hallucinations. Researchershave found that the drug, which is also known as ecstasy or molly,may be useful in the treatment of  a range of mental health conditions, including anxiety. A recentlyconducted medical trial also found that the drug, which is popularin rave culture, could effectively treat post-traumatic stressdisorder. Post-traumatic stress disorder is a mental healthcondition that’s usually triggered when an individual witnesses orexperiences a traumatic event. Symptoms may include nightmares,flashbacks and severe anxiety, among other things. The trial wascarried out by Multidisciplinary Association for PsychedelicStudies (MAPS),which is a not-for-profit organization that’s focused on raisingawareness of psychedelic substances. For their study, theresearchers recruited 90 participants suffering from severe post-traumatic disorder. Each of thesepatients received either a placebo or a 120 mg or 80 mg dose ofMDMA. Once the treatment was administered, the patients were givenheadphones to listen to music and eye masks to wear while they satwith the researchers to observe how they reacted. If these drugshit the market, psychedelic startups such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are likely to attract a lot more investor interest given theupward potential that approved drugs present.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Tuesday's trading session at $0.0333, up 21.3557%, on 250,332 volume. The average volume for the last 3 months is 250,332 and the stock's 52-week low/high is $0.022/$0.1376.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.